353 related articles for article (PubMed ID: 27979579)
1. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.
Danne T; Biester T; Kapitzke K; Jacobsen SH; Jacobsen LV; Petri KCC; Hale PM; Kordonouri O
J Pediatr; 2017 Feb; 181():146-153.e3. PubMed ID: 27979579
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
Mastrandrea LD; Witten L; Carlsson Petri KC; Hale PM; Hedman HK; Riesenberg RA
Pediatr Obes; 2019 May; 14(5):e12495. PubMed ID: 30653847
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Kelly AS; Auerbach P; Barrientos-Perez M; Gies I; Hale PM; Marcus C; Mastrandrea LD; Prabhu N; Arslanian S;
N Engl J Med; 2020 May; 382(22):2117-2128. PubMed ID: 32233338
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Klein DJ; Battelino T; Chatterjee DJ; Jacobsen LV; Hale PM; Arslanian S;
Diabetes Technol Ther; 2014 Oct; 16(10):679-87. PubMed ID: 25036533
[TBL] [Abstract][Full Text] [Related]
5. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
[TBL] [Abstract][Full Text] [Related]
6. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L
BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146
[TBL] [Abstract][Full Text] [Related]
9. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
11. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
Mader JK; Jensen L; Ingwersen SH; Christiansen E; Heller S; Pieber TR
Clin Pharmacokinet; 2016 Nov; 55(11):1457-1463. PubMed ID: 27282158
[TBL] [Abstract][Full Text] [Related]
13. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
Weghuber D; Forslund A; Ahlström H; Alderborn A; Bergström K; Brunner S; Cadamuro J; Ciba I; Dahlbom M; Heu V; Hofmann J; Kristinsson H; Kullberg J; Ladinger A; Lagler FB; Lidström M; Manell H; Meirik M; Mörwald K; Roomp K; Schneider R; Vilén H; Widhalm K; Zsoldos F; Bergsten P
Pediatr Obes; 2020 Jul; 15(7):e12624. PubMed ID: 32062862
[TBL] [Abstract][Full Text] [Related]
14. Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.
Bensignor MO; Bramante CT; Bomberg EM; Fox CK; Hale PM; Kelly AS; Mamadi R; Prabhu N; Harder-Lauridsen NM; Gross AC
Pediatr Obes; 2023 Sep; 18(9):e13061. PubMed ID: 37264767
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.
Jiang J; Zhang J; Jacobsen LV; Hu P
J Clin Pharmacol; 2011 Dec; 51(12):1620-7. PubMed ID: 21273395
[TBL] [Abstract][Full Text] [Related]
19. Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.
Petri KC; Jacobsen LV; Klein DJ
Clin Pharmacokinet; 2015 Jun; 54(6):663-70. PubMed ID: 25603819
[TBL] [Abstract][Full Text] [Related]
20. Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.
Nexøe-Larsen CC; Sørensen PH; Hausner H; Agersnap M; Baekdal M; Brønden A; Gustafsson LN; Sonne DP; Vedtofte L; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Nov; 20(11):2557-2564. PubMed ID: 29892986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
